Gudang Garam Stock Continues to Decline in Indonesia's Anti-Smoking Campaign

Dec.08.2022
Gudang Garam Stock Continues to Decline in Indonesia's Anti-Smoking Campaign
Susilo Wonowidjojo's wealth declined due to falling stocks of his family's cigarette company, Gudang Garam, amid anti-smoking campaigns.

Susilo Wonowidjojo's wealth has further declined this year as the stock of his family's cigarette manufacturer Gudang Garam continues its three-year slump amid the Indonesian government's anti-smoking campaign. His net worth dropped by 27% to $3.5 billion, placing him at 14th on Indonesia's richest 50 list, down seven spots from last year.


Despite a slight improvement in sales during the first nine months of 2022, net profit has decreased by 64% year-on-year to 15 trillion Indonesian rupiahs (96 million US dollars), primarily due to the government's increase in tobacco consumption tax in January (following a 27% drop in revenue in 2021). Taxes make up over 85% of the company's total sales costs, resulting in a profit margin of 1.6%, down from 4.4% last year. Additionally, in November, Finance Minister Sri Mulyani Indrawati announced additional tax increases in 2023 and 2024. The company has stated its plans to raise prices.


In recent years, Indonesia has strengthened its measures to combat smoking, especially among young people. Approximately one quarter of the country's 276 million population smoke cigarettes. Overseas sales for Gudang Garam have also declined, dropping nearly 15% year-on-year in 2021 to 1.8 billion cigarettes. The company diversified its operations in 2019 with the construction of toll roads and is currently building the Dhoho airport in Kediri, East Java at a cost of 600 million dollars, which is expected to open in October of next year.


Gudang Garam was founded in 1958 by Susilo's father, Surya Wonowidjojo. Since 2009, Susilo has served as the CEO of the Kediri-based company, with his sister Juni Setiawati serving as the executive commissioner. In June, Susilo's son Indra was appointed as the Vice President Director.


2FIRSTS will continue to report on this issue, with further updates available on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BlackRock Enters Top Shareholder Ranks as KT&G Holding Reaches 5.01%
BlackRock Enters Top Shareholder Ranks as KT&G Holding Reaches 5.01%
BlackRock increased its stake in KT&G to 5.01% after purchasing 68,646 shares, bringing total holdings to 5,914,169 shares and triggering Korea’s large-shareholding disclosure rules. KT&G shares climbed to an all-time intraday high of 153,900(about US$106.19) won and closed at a record 152,900(about US$105.50) won. KT&G is set to report earnings on Feb. 5, with consensus pointing to year-on-year growth in revenue and operating profit.
Jan.30 by 2FIRSTS.ai
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
As nicotine pouches gain global traction as a lower-risk alternative to smoking, questions are emerging about their potential oral health effects. In a 2Firsts interview, Stingfree AB founder Bengt Wiberg discusses why gum irritation and oral lesions warrant closer scrutiny within the broader framework of tobacco harm reduction.
Jan.06
2Firsts Interview | Prague Move Puts Eastern Europe in Focus for Nicotine Industry Event EVO NXT
2Firsts Interview | Prague Move Puts Eastern Europe in Focus for Nicotine Industry Event EVO NXT
EVO NXT will move to Prague in April 2026. As an event’s official media partner for four consecutive years, 2Firsts recently interviewed the organisers, who said the relocation reflects strong growth in Eastern European markets for alternative nicotine products. They described EVO NXT as not a traditional trade fair but a business festival shaped by rapid changes in regulation, markets and technological innovation across the global nicotine industry.
Feb.03
Mexico to impose an absolute ban on the commercialization, import and sale of vapes from Jan. 16, 2026
Mexico to impose an absolute ban on the commercialization, import and sale of vapes from Jan. 16, 2026
Mexico will enforce an absolute ban on the commercialization, import and sale of vapes and e-cigarettes from January 16, 2026, under a reform published in the Official Journal of the Federation (DOF) amending the General Health Law.
Jan.16 by 2FIRSTS.ai
Russian Region Targets Youth Vaping and Night Alcohol Sales
Russian Region Targets Youth Vaping and Night Alcohol Sales
The Speaker of the Legislative Assembly of Russia’s Nizhny Novgorod Region said efforts to curb night-time alcohol sales and the spread of e-cigarettes will continue in 2026. While illegal alcohol trade has largely been eliminated, youth vaping remains a major concern. Regional authorities are seeking federal approval to allow local governments to impose stricter restrictions on vape sales, alongside increased health education initiatives.
Dec.22 by 2FIRSTS.ai
Philippine FDA Requires Licenses for Vape Products with Medical Claims
Philippine FDA Requires Licenses for Vape Products with Medical Claims
The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.
Dec.22 by 2FIRSTS.ai